论文部分内容阅读
目的对比观察替比夫定和拉米夫定治疗妊娠期轻度乙型肝炎病毒感染者的疗效和安全性。方法选择入医院就诊的240例妊娠期轻度感染乙肝的患者且为妊娠28周以上的妊娠者,将其随机分为研究组和对照组各120例。2组均给予常规保肝治疗,在此基础上研究组给予替比夫定治疗,对照组给予拉米夫定治疗。观察2组孕妇治疗后4周、8周疗效及安全性。结果治疗4周、8周后研究组治疗有效率均高于对照组(P<0.05);研究组和对照组分别有3例(2.50%)和4例(3.33%)出现了一过性的ALT轻度的增高,2组差异无统计学意义(P>0.05),且上升水平不高于正常值的6倍,且在治疗过程中其水平均自行的恢复至正常血清水平。结论替比夫定与拉米夫定治疗妊娠期轻度乙型肝炎病毒感染均具较好的安全性,但替比夫定治疗妊娠期轻度乙型肝炎感染疗效优于拉米夫定,具更高的临床价值。
Objective To compare the efficacy and safety of telbivudine and lamivudine in the treatment of mild hepatitis B virus infection during pregnancy. Methods A total of 240 pregnant women with mild hepatitis B during pregnancy were enrolled in this study. Pregnant women with gestational age above 28 weeks were randomly divided into study group (120 cases) and control group (120 cases). Both groups were given conventional hepatoprotective therapy. On this basis, the study group was treated with telbivudine, while the control group was treated with lamivudine. Two groups of pregnant women were observed after 4 weeks, 8 weeks efficacy and safety. Results After treatment for 4 weeks and 8 weeks, the effective rate of the study group was higher than that of the control group (P <0.05). Three cases (2.50%) and 4 cases (3.33%) of the study group and the control group had a transient There was no significant difference between the two groups (P> 0.05), and the level of ALT was not higher than 6 times of the normal value. The levels of ALT recovered to normal serum levels during the treatment. Conclusion Telbivudine and lamivudine have better safety in treating mild hepatitis B virus infection during pregnancy, but telbivudine is superior to lamivudine in treating mild hepatitis B infection during pregnancy, With higher clinical value.